Tenet Reports Strong Third Quarter 2026 Results;
Net income available to common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third quarter 2025
increased 79.5% to $6.64 in third quarter 2026 compared to $3.70 in third quarter 2025
increased 23.3% over third quarter 2025 to $1.355 billion; Third quarter 2026 Adjusted EBITDA margin was 24.1%
Third quarter 2026 Ambulatory Care Adjusted EBITDA of $537 million increased 9.1% over third quarter 2025
FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05 billion to $5.20 billion, a $195 million increase at the midpoint of the range; FY 2026 Adjusted Free Cash Flow outlook now expected to be in the range of $2.825 billion to $3.125 billion, a $100 million increase
Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2026.
"Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our focus on patient-centered care, support for physician partners, technology-enabled growth and operating initiatives continue to deliver strong margins and free cash flow." Page 1 Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows:
• Net income available to the Company’s common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share, versus $342 million, or $3.86 per diluted share, in third quarter 2025.
• The Company had previously entered into certain agreements with CommonSpirit Health, related to Conifer Health Solutions, LLC ("Conifer"), whereby the parties agreed, in part, to the early conclusion and transition of our revenue cycle management services by December 31, 2026, (collectively, the "RCM Agreements").
• The transition of certain revenue cycle management services under the RCM Agreements occurred during the third quarter of 2026 and will be substantially complete by October 30, 2026. As a result of this revised timeline, during the three months ended September 30, 2026, we recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million. These are timing-related adjustments and as such, do not impact total or full year 2026 expectations for revenue from contract termination or net operating revenues associated with the RCM Agreements.
• In addition, we recognized a benefit of approximately $50 million during the three months ended September 30, 2026 due to various transition activities, including efficiencies from the revised timeline described above. This, combined with the $97 million timing-related adjustment to net operating revenue mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147 million in the third quarter of 2026.
• Adjusted EBITDA 1 was $1.355 billion in third quarter 2026 compared to $1.099 billion in third quarter 2025, reflecting strong same facility revenue growth and disciplined expense management partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the $147 million favorable net impact described above. Page 2 Balance Sheet and Cash Flows
• Net cash flows provided by operating activities for the nine months ended September 30, 2026 were $3.507 billion versus $2.809 billion for the nine months ended September 30, 2025.
• The Company generated adjusted free cash flow 1 of $2.524 billion for the nine months ended September 30, 2026 versus $2.247 billion for the nine months ended September 30, 2025.
• In the three months ended September 30, 2026, the Company repurchased 970,000 shares of common stock for $255 million. In the nine months ended September 30, 2026, the Company repurchased 7.99 million shares of common stock for $1.615 billion.
• In September 2026, the Company completed a private placement of $2.0 billion in aggregate principal amount of newly issued 6.250% senior notes maturing in 2034. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion aggregate principal amount then outstanding of its 5.125% senior secured first lien notes due in 2027 and the partial redemption of $500 million outstanding of its 6.125% senior notes due in 2028.
• The Company’s ratio of net debt to Adjusted EBITDA 1 was 2.11x at September 30, 2026 compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025. Page 3
Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2026, USPI had interests in 535 ambulatory surgery centers (406 consolidated) and 25 surgical hospitals (seven consolidated) in 37 states.
• Third quarter 2026 net operating revenues increased 7.5% compared to third quarter 2025 driven by strong growth in consolidated same-facility net patient service revenues, acquisitions of facilities, and increased service lines.
• Surgical business same-facility system-wide net patient service revenues increased 4.5% in third quarter 2026 compared to third quarter 2025, with cases down 1.5% and net revenue per case up 6.1%. Net revenue per case growth was driven by higher acuity and favorable service mix.
• Third quarter 2026 Adjusted EBITDA increased 9.1% compared to third quarter 2025, due to strong growth in same-facility net patient service revenues, disciplined expense management, and contributions from acquisitions. Page 4 Hospital Operations and Services (Hospital) Segment
Tenet’s Hospital business segment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro- hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.
• Third quarter 2026 net operating revenues increased 6.1% from third quarter 2025 driven by an increase in adjusted admissions as well as continued pricing strength, partially offset by unfavorable payer mix due to lower exchange admissions. In addition, third quarter 2026 net operating revenues include a timing-related benefit of $97 million associated with the RCM Agreements as described on page 2.
• Same-hospital net patient service revenue per adjusted admission increased 0.2% year-over-year for third quarter 2026 primarily due to strength in commercial employer net patient revenues offset by unfavorable payer mix related to lower exchange admissions.
• Adjusted EBITDA in third quarter 2026 was $818 million compared to $607 million in third quarter 2025, reflecting strong growth in same-hospital revenue and disciplined expense management, partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the net favorable impact of $147 million from transition activities described on page 2.
• In the third quarter of 2026, the Hospital segment recognized a $32 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years. Third quarter 2025 results included a $38 million favorable pre-tax impact for additional Medicaid supplemental revenues related to prior years. Page 5
Tenet’s Outlook for full year 2026 (consolidated and by segment) follows. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues.
CONSOLIDATED($ in millions, except per share FY 2026 Outlook amounts) Net operating revenues7 $22,050 to $22,450 Net income available to Tenet common shareholders $2,973 to $3,078 Adjusted EBITDA $5,050 to $5,200 Adjusted EBITDA margin 22.9% to 23.2% Diluted income per common share $35.82 to $37.08 Adjusted net income $1,830 to $1,910 Adjusted diluted earnings per share $22.05 to $23.01 Equity in earnings of unconsolidated affiliates $265 to $275 Depreciation and amortization $865 to $915 Interest expense $815 to $825 Income tax expense5 $1,135 to $1,170 Net income available to NCI $910 to $960 Weighted average diluted common shares ~83 million Net cash provided by operating activities $3,885 to $4,315 Adjusted net cash provided by operating activities $3,525 to $3,925 Capital expenditures $700 to $800 Free cash flow $3,185 to $3,515 Adjusted free cash flow $2,825 to $3,125 NCI cash distributions $900 to $970
Ambulatory Segment($ in millions) FY 2026 Outlook Net operating revenues $5,530 to $5,670 Adjusted EBITDA $2,160 to $2,220 NCI $865 to $895 Adjusted EBITDA less NCI $1,295 to $1,325 Changes versus prior year6: Same-facility system-wide revenues Up 3.0% to 6.0%
Hospital Segment($ in millions) FY 2026 Outlook Net operating revenues7 $16,520 to $16,780 Adjusted EBITDA $2,890 to $2,980 NCI $45 to $65 Changes versus prior year6: Inpatient admissions Up 1.0% to 2.0% Adjusted admissions Up 1.0% to 2.0%
Tenet management will discuss the Company’s third quarter 2026 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on October 29, 2026. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.
The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on October 29, 2026. Page 7
This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission .
1. Tables and discussions throughout this earnings release include certain financial measures, including those related to our full year 2026 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non- GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.
2. Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.
3. For 2026, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2025 through September 30, 2026. Amounts associated with physician practices are excluded.
4. Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.
5. Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less NCI expense plus permanent differences, and non-deductible interest expense.
6. Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.
7. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues. Page 8
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
Investor Contact Media Contact Will McDowell Olivia E. Nadler 469-893-2387 469-893-6352 [email protected] [email protected]
The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non- GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.
• Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, (12) income (loss) from divested and closed businesses (i.e., health plan businesses) and (13) revenue from contract termination. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.
• Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.
• Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses), (7) revenue from contract termination and (8) the associated impact of these items on taxes and noncontrolling interests. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.
• Free Cash Flow is defined by the Company as (1) net cash provided by (used in)
• Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.
• Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, (2) net cash provided by (used in) operating activities from discontinued operations and (3) cash received for contract termination defined above.
The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.
The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.
These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Because these measures exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.
See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below. Page 10
Description Page Consolidated Statements of Operations 12 Consolidated Balance Sheets 14 Consolidated Statements of Cash Flows 15 Segment Reporting 16 Table #1–Reconciliations of 17 NetIncometoAdjusted Net Income Table #2–Reconciliations of Net Income 18 toAdjusted EBITDA Table #3–Reconciliations of Net Cash Provided by Operating Activities to Free 19 Cash Flow and Adjusted Free Cash Flow Table #4–Reconciliations of Outlook Net 20 Income to Outlook Adjusted Net Income Table #5–Reconciliations of Outlook Net 21 Income to Outlook Adjusted EBITDA Table #6–Reconciliations of Outlook Net Cash Provided byOperating Activities to 22 Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow
(Dollars in September 30, December 31, millions) 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 2,674 $ 2,883 Accounts receivable 2,595 2,565 Inventories of supplies, 340 348 at cost Assets held for sale 62 62 Other current assets 2,757 1,991 Total current assets 8,428 7,849 Investments and other 3,958 2,883 assets Deferred income taxes 49 84 Property and equipment, at cost, less accumulated depreciation 6,290 6,315 and amortization Goodwill 11,641 11,198 Other intangible assets, at cost, less 1,226 1,348 accumulated amortization Total assets $ 31,592 $ 29,677 LIABILITIES AND EQUITY Current liabilities: Current portion of $ 164 $ 79 long-term debt Accounts payable 1,387 1,360 Accrued compensation and 873 858 benefits Professional and general liability 317 276 reserves Accrued interest payable 213 81 Income tax payable 22 — Other current liabilities 2,342 1,809 Total current liabilities 5,318 4,463 Long-term debt, net of 13,079 13,092 current portion Professional and general liability 979 951 reserves Defined benefit plan 238 245 obligations Deferred income taxes 529 240 Other long-term 1,855 1,713 liabilities Total liabilities 21,998 20,704 Commitments and contingencies Redeemable noncontrolling interests in 2,179 2,956 equity of consolidated subsidiaries Equity: Shareholders’ equity: Common stock 8 8 Additional paid-in capital 5,236 4,914 Accumulated other -178 -181 comprehensive loss Retained earnings 6,943 4,415 Common stock in treasury, -6,565 -4,936 at cost Total shareholders’ equity 5,444 4,220 Noncontrolling interests 1,971 1,797 Total equity 7,415 6,017 Total liabilities and $ 31,592 $ 29,677 equity
(Dollars in Nine Months Ended millions) September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 3,170 $ 1,723 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 661 632 amortization Deferred income tax 324 51 expense Stock-based 104 79 compensation expense Impairment and restructuring charges, 92 66 and acquisition-related costs Litigation and 36 34 investigation costs Net gains on sales, consolidation and -43 -4 deconsolidation of facilities Loss from early 5 — extinguishment of debt Equity in earnings of unconsolidated affiliates, net of -11 -13 distributions received Amortization of debt discount and debt 16 18 issuance costs Other items, net -11 -5 Changes in cash from operating assets and liabilities: Accounts receivable -11 68 Inventories and other 211 -58 current assets Income taxes 63 15 Accounts payable, accrued expenses and -1,042 237 other current liabilities Other long-term 46 50 liabilities Payments for restructuring charges, acquisition-related -103 -84 costs, and litigation costs and settlements Net cash provided by operating 3,507 2,809 activities Cash flows from investing activities: Purchases of property -546 -646 and equipment Purchases of businesses or joint venture -201 -266 interests, net of cash acquired Proceeds from sales of facilities and 11 18 other assets Proceeds from sales of marketable 66 74 securities and long-term investments Purchases of marketable securities and -122 -69 long-term investments Other items, net -26 3 Net cash used in -818 -886 investing activities Cash flows from financing activities: Repayments of -2,087 -90 borrowings Proceeds from 2,041 21 borrowings Repurchases of common -1,615 -1,188 stock Debt issuance costs -22 — Distributions paid to noncontrolling -614 -585 interests Proceeds from the sale of noncontrolling 33 27 interests Purchases of noncontrolling -583 -88 interests Repayments of advances from managed care — -33 payers Taxes paid related to net share settlement, net of proceeds from shares -84 -47 issued under stock‑based compensation plans Other items, net 33 16 Net cash used in -2,898 -1,967 financing activities Net decrease in cash and cash -209 -44 equivalents Cash and cash equivalents at 2,883 3,019 beginning of period Cash and cash equivalents at end of $ 2,674 $ 2,975 period Supplemental disclosures: Interest paid, net of capitalized $ -464 $ -499 interest Income tax payments, $ -493 $ -329 net
Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available to Common Shareholders
Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA
(Dollars in millions) 2026 Q3 YTD ───────────────────────────────────────────────────────────────────────────── Net cash provided by operating $ 1,281 $ 3,507 activities Purchases of property and equipment -198 -546 Free cash flow $ 1,083 $ 2,961 Net cash used in investing activities $ -298 $ -818 Net cash used in financing activities $ -479 $ -2,898 Net cash provided by operating $ 1,281 $ 3,507 activities Less: Payments for restructuring charges, acquisition-related costs, and -19 -103 litigation costs and settlements Cash received for contract termination — 540 Adjusted net cash provided by operating 1,300 3,070 activities Purchases of property and equipment -198 -546 Adjusted free cash flow $ 1,102 $ 2,524
2025 (Dollars in millions) Q3 YTD ─────────────────────────────────────────────────────────────────────── Net cash provided by operating $ 1,058 $ 2,809 activities Purchases of property and equipment -280 -646 Free cash flow $ 778 $ 2,163 Net cash used in investing activities $ -385 $ -886 Net cash used in financing activities $ -323 $ -1,967 Net cash provided by operating $ 1,058 $ 2,809 activities Less: Payments for restructuring charges, acquisition-related costs, and -3 -84 litigation costs and settlements Adjusted net cash provided by operating 1,061 2,893 activities Purchases of property and equipment -280 -646 Adjusted free cash flow $ 781 $ 2,247
Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available to Common Shareholders
(Dollars in millions, except per share amounts) FY 2026 Low High ────────────────────────────────────────────────────────────────────────────── Net income available to Tenet Healthcare $ 2,973 $ 3,078 Corporation common shareholders Less: Revenue from contract termination 1,650 1,650 Impairment and restructuring charges, acquisition-related costs, and -180 -150 litigation costs and settlements(1) Net gains on sales, consolidation and 43 43 deconsolidation of facilities(2) Loss from early extinguishment of -5 -5 debt(2) Tax and noncontrolling interests impact -365 -370 of above items Adjusted net income available to common $ 1,830 $ 1,910 shareholders Diluted earnings per share $ 35.82 $ 37.08 Less: Revenue from contract termination 19.88 19.88 Impairment and restructuring charges, -2.17 -1.81 acquisition-related costs, and litigation costs and settlements Net gains on sales, consolidation and 0.52 0.52 deconsolidation of facilities Loss from early extinguishment of -0.06 -0.06 debt Tax and noncontrolling interests impact -4.40 -4.46 of above items Adjusted diluted earnings per $ 22.05 $ 23.01 share Weighted average dilutive shares 83,000 83,000 outstanding (in thousands) (1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. (2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.
Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA
(Dollars in millions) FY 2026 Low High ────────────────────────────────────────────────────────────────────────────── Net income available to Tenet Healthcare $ 2,973 $ 3,078 Corporation common shareholders Less: Net income available to noncontrolling -910 -960 interests Income tax expense -1,135 -1,170 Interest expense -825 -815 Loss from early extinguishment of -5 -5 debt(2) Other non-operating income, 150 200 net Net gains on sales, consolidation and 43 43 deconsolidation of facilities(2) Impairment and restructuring charges, acquisition-related costs, -180 -150 and litigation costs and settlements(1) Depreciation and -865 -915 amortization Revenue from contract 1,650 1,650 termination Adjusted EBITDA $ 5,050 $ 5,200 Net income available to Tenet Healthcare $ 2,973 $ 3,078 Corporation common shareholders Net operating revenues $ 22,050 $ 22,450 Net income available to Tenet Healthcare Corporation common 13.5 % 13.7 % shareholders as a % of net operating revenues Adjusted EBITDA as a % of net operating 22.9 % 23.2 % revenues (Adjusted EBITDA margin) (1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. (2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow
FY 2026 (Dollars in millions) Low High ─────────────────────────────────────────────────────────────────────────── Net cash provided by operating $ 3,885 $ 4,315 activities Purchases of property and equipment -700 -800 Free cash flow $ 3,185 $ 3,515 Net cash provided by operating $ 3,885 $ 4,315 activities Less: Payments for restructuring charges, acquisition-related costs and litigation -180 -150 costs and settlements(1) Cash received for contract termination 540 540 Adjusted net cash provided by operating 3,525 3,925 activities Purchases of property and equipment -700 -800 Adjusted free cash flow(2) $ 2,825 $ 3,125 (1) The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs or settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. (2) The Company’s definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.
Full text with the tables
Exhibit 99.1
Tenet Reports Strong Third Quarter 2026 Results;
Raises 2026 Financial Outlook
•
Net income available to common shareholders in third quarter 2026 was $1.000
billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third
quarter 2025
•
Adjusted diluted earnings per share
1
increased 79.5% to $6.64 in third quarter 2026 compared to $3.70 in third
quarter 2025
•
Third quarter 2026 Consolidated Adjusted EBITDA
1
increased 23.3% over third quarter 2025 to $1.355 billion; Third quarter 2026
Adjusted EBITDA margin was 24.1%
•
Third quarter 2026 Ambulatory Care Adjusted EBITDA of $537 million increased
9.1% over third quarter 2025
•
FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05
billion to $5.20 billion, a $195 million increase at the midpoint of the range;
FY 2026 Adjusted Free Cash Flow outlook now expected to be in the range of
$2.825 billion to $3.125 billion, a $100 million increase
DALLAS — October 29, 2026 —
Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for
the quarter ended September 30, 2026.
"Our outperformance in the third quarter of 2026 was driven by sustained
strength in same-store revenue growth and effective expense management," said
Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our focus on
patient-centered care, support for physician partners, technology-enabled growth
and operating initiatives continue to deliver strong margins and free cash
flow."
Page 1
Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows:
Three Nine
Months Months
Ended Ended
Septe… Septem…
30, 30,
($ in
milli…
except 2026 2025 2026 2025
per
share
resul…
Net
opera… $5,631 $5,289 $16,627 $15,7…
reven…
Net
income
avail…
to $1,000 $342 $2,528 $1,036
Tenet
common
share…
Net
income
avail…
to
Tenet $12.41 $3.86 $30.08 $11.28
common
share…
per
dilut…
share
Adjus… $1,355 $1,099 $3,821 $3,383
EBITD…
Adjus…
dilut…
earni… $6.64 $3.70 $17.50 $12.10
per
share1
• Net income available to the Company’s common shareholders in third quarter
2026 was $1.000 billion, or $12.41 per diluted share, versus $342 million, or
$3.86 per diluted share, in third quarter 2025.
• The Company had previously entered into certain agreements with CommonSpirit
Health, related to Conifer Health Solutions, LLC ("Conifer"), whereby the
parties agreed, in part, to the early conclusion and transition of our revenue
cycle management services by December 31, 2026, (collectively, the "RCM
Agreements").
• The transition of certain revenue cycle management services under the RCM
Agreements occurred during the third quarter of 2026 and will be substantially
complete by October 30, 2026. As a result of this revised timeline, during the
three months ended September 30, 2026, we recognized cumulative catch-up
adjustments that increased revenue from contract termination by $233 million and
net operating revenues by $97 million. These are timing-related adjustments and
as such, do not impact total or full year 2026 expectations for revenue from
contract termination or net operating revenues associated with the RCM
Agreements.
• In addition, we recognized a benefit of approximately $50 million during the
three months ended September 30, 2026 due to various transition activities,
including efficiencies from the revised timeline described above. This, combined
with the $97 million timing-related adjustment to net operating revenue
mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147
million in the third quarter of 2026.
• Adjusted EBITDA 1 was $1.355 billion in third quarter 2026 compared to $1.099
billion in third quarter 2025, reflecting strong same facility revenue growth
and disciplined expense management partially offset by unfavorable payer mix due
to lower exchange admissions. Results also include the $147 million favorable
net impact described above.
Page 2
Balance Sheet and Cash Flows
• Net cash flows provided by operating activities for the nine months ended
September 30, 2026 were $3.507 billion versus $2.809 billion for the nine months
ended September 30, 2025.
• The Company generated adjusted free cash flow 1 of $2.524 billion for the nine
months ended September 30, 2026 versus $2.247 billion for the nine months ended
September 30, 2025.
• In the three months ended September 30, 2026, the Company repurchased 970,000
shares of common stock for $255 million. In the nine months ended September 30,
2026, the Company repurchased 7.99 million shares of common stock for $1.615
billion.
• In September 2026, the Company completed a private placement of $2.0 billion
in aggregate principal amount of newly issued 6.250% senior notes maturing in
2034. The Company used the net proceeds from the sale of the notes, after
payment of fees and expenses, to finance, together with cash on hand, the
redemption of all $1.5 billion aggregate principal amount then outstanding of
its 5.125% senior secured first lien notes due in 2027 and the partial
redemption of $500 million outstanding of its 6.125% senior notes due in 2028.
• The Company’s ratio of net debt to Adjusted EBITDA 1 was 2.11x at September
30, 2026 compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025.
Page 3
Ambulatory Care (Ambulatory) Segment
Tenet’s Ambulatory business segment is comprised of the operations of United
Surgical Partners International (USPI). As of September 30, 2026, USPI had
interests in 535 ambulatory surgery centers (406 consolidated) and 25 surgical
hospitals (seven consolidated) in 37 states.
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
Am…
se…
re… 2026 2025 2026 2025
in
mi…
Re…
Net
op… $1,… $1,… $4,… $3,…
re…
Sa…
sy…
net $2,… $2,… $6,… $6…
pa…
se…
re…
Ch…
ve…
the
Pr…
Pe…
Sa…
sy…
net 4.5 % 8.3 % 5.1 % 7.5 %
pa…
se…
re…
Sa…
sy…
net
pa… 6.1 % 6.1 % 6.0 % 7.7 %
se…
re…
per
ca…
Sa…
sy… -1.5 % 2.1 % -0.8 % -0.2 %
su…
ca…
Sa…
sy…
su…
ca… -1.5 % 2.1 % -0.8 % 0.4 %
on
sa…
day
ba…
Ad…
EB…
Ma…
and
NCI
Ad… $537 $492 $1,… $1,…
EB…
Ad…
EB… 39.2 % 38.6 % 38.3 % 38.7 %
ma…
Ad…
EB… $327 $292 $948 $8…
le…
NCI
• Third quarter 2026 net operating revenues increased 7.5% compared to third
quarter 2025 driven by strong growth in consolidated same-facility net patient
service revenues, acquisitions of facilities, and increased service lines.
• Surgical business same-facility system-wide net patient service revenues
increased 4.5% in third quarter 2026 compared to third quarter 2025, with cases
down 1.5% and net revenue per case up 6.1%. Net revenue per case growth was
driven by higher acuity and favorable service mix.
• Third quarter 2026 Adjusted EBITDA increased 9.1% compared to third quarter
2025, due to strong growth in same-facility net patient service revenues,
disciplined expense management, and contributions from acquisitions.
Page 4
Hospital Operations and Services (Hospital) Segment
Tenet’s Hospital business segment is primarily comprised of acute care and
specialty hospitals, imaging centers, ancillary outpatient facilities, micro-
hospitals and physician practices. It also provides comprehensive end-to-end and
focused point services, including hospital and physician revenue cycle
management, patient communications and engagement support and value-based care
solutions.
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
Ho…
se…
re… 2026 2025 2026 2025
in
mi…
Re…
Net
op… $4,… $4,… $12… $1…
re…
Sa…
net
pa… $3,… $3,… $10… $10…
se…
re…
Sa…
Vo…
Ch…
ve…
the
Pr…
Pe…
Ad… 2.8 % 1.5 % 1.8 % 2.5 %
Ad… 3.2 % 1.4 % 2.1 % 1.6 %
ad…
Ou…
vi…
(i… 0.1 % -1.5 % -0.9 % -1.4 %
ou…
ER
vi…
Em…
Ro…
vi… 4.0 % -2.0 % 0.9 % -1.8 %
(i…
and
ou…
Ho… -1.1 % 0.7 % -0.9 % -0.8 %
su…
Ad…
EB…
Ad… $818 $607 $2,… $1,…
EB…
Ad…
EB… 19.2 % 15.1 % 18.0 % 16.1 %
ma…
• Third quarter 2026 net operating revenues increased 6.1% from third quarter
2025 driven by an increase in adjusted admissions as well as continued pricing
strength, partially offset by unfavorable payer mix due to lower exchange
admissions. In addition, third quarter 2026 net operating revenues include a
timing-related benefit of $97 million associated with the RCM Agreements as
described on page 2.
• Same-hospital net patient service revenue per adjusted admission increased
0.2% year-over-year for third quarter 2026 primarily due to strength in
commercial employer net patient revenues offset by unfavorable payer mix related
to lower exchange admissions.
• Adjusted EBITDA in third quarter 2026 was $818 million compared to $607
million in third quarter 2025, reflecting strong growth in same-hospital revenue
and disciplined expense management, partially offset by unfavorable payer mix
due to lower exchange admissions. Results also include the net favorable impact
of $147 million from transition activities described on page 2.
• In the third quarter of 2026, the Hospital segment recognized a $32 million
favorable pre-tax impact associated with additional Medicaid supplemental
revenues related to prior years. Third quarter 2025 results included a $38
million favorable pre-tax impact for additional Medicaid supplemental revenues
related to prior years.
Page 5
2026 Outlook
1
Tenet’s Outlook for full year 2026 (consolidated and by segment) follows.
Contract termination revenue recognized from the early conclusion of the RCM
Agreements is not included in net operating revenues.
CONSOLIDATED($ in millions, except per share FY 2026 Outlook
amounts)
Net operating revenues7 $22,050 to $22,450
Net income available to Tenet common shareholders $2,973 to $3,078
Adjusted EBITDA $5,050 to $5,200
Adjusted EBITDA margin 22.9% to 23.2%
Diluted income per common share $35.82 to $37.08
Adjusted net income $1,830 to $1,910
Adjusted diluted earnings per share $22.05 to $23.01
Equity in earnings of unconsolidated affiliates $265 to $275
Depreciation and amortization $865 to $915
Interest expense $815 to $825
Income tax expense5 $1,135 to $1,170
Net income available to NCI $910 to $960
Weighted average diluted common shares ~83 million
Net cash provided by operating activities $3,885 to $4,315
Adjusted net cash provided by operating activities $3,525 to $3,925
Capital expenditures $700 to $800
Free cash flow $3,185 to $3,515
Adjusted free cash flow $2,825 to $3,125
NCI cash distributions $900 to $970
Page 6
Ambulatory Segment($ in millions) FY 2026 Outlook
Net operating revenues $5,530 to $5,670
Adjusted EBITDA $2,160 to $2,220
NCI $865 to $895
Adjusted EBITDA less NCI $1,295 to $1,325
Changes versus prior year6:
Same-facility system-wide revenues Up 3.0% to 6.0%
Hospital Segment($ in millions) FY 2026 Outlook
Net operating revenues7 $16,520 to $16,780
Adjusted EBITDA $2,890 to $2,980
NCI $45 to $65
Changes versus prior year6:
Inpatient admissions Up 1.0% to 2.0%
Adjusted admissions Up 1.0% to 2.0%
Management’s Webcast Discussion of Results
Tenet management will discuss the Company’s third quarter 2026 results in a
webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on
October 29, 2026. Investors can access the webcast through the Company’s website
at www.tenethealth.com/investors.
The slide presentation associated with the webcast referenced above, a copy of
this earnings press release, and a related supplemental financial disclosures
document will be available on the Company’s Investor Relations website on
October 29, 2026.
Page 7
Cautionary Statement
This release contains “forward-looking statements” - that is, statements that
relate to future, not past, events. In this context, forward-looking statements
often address the Company’s expected future business and financial performance
and financial condition, and often contain words such as “expect,” “anticipate,”
“assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,”
“predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking
statements by their nature address matters that are, to different degrees,
uncertain. Particular uncertainties that could cause the Company’s actual
results to be materially different than those expressed in the Company’s
forward-looking statements include, but are not limited to the factors disclosed
under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the
year ended December 31, 2025 and other filings with the Securities and Exchange
Commission .
Footnotes
1. Tables and discussions throughout this earnings release include certain
financial measures, including those related to our full year 2026 Outlook, that
are not in accordance with accounting principles generally accepted in the
United States of America (GAAP). Reconciliations of GAAP measures to the
Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the
end of this earnings release. Management’s reasoning for the use of these non-
GAAP measures and descriptions of the various non-GAAP measures are included in
the Non-GAAP Financial Measures section of this earnings release.
2. Same-facility system-wide revenues and statistical information include the
results of the facilities in which the Ambulatory segment has an investment that
are not consolidated by Tenet. To help analyze the segment’s results of
operations, management uses system-wide measures, which include revenues and
cases of both consolidated and unconsolidated facilities.
3. For 2026, same-hospital revenues and statistical data include those for
hospitals and hospital-affiliated outpatient centers operated by the Company’s
Hospital segment continuously from January 1, 2025 through September 30, 2026.
Amounts associated with physician practices are excluded.
4. Adjusted admissions represent actual patient admissions adjusted to include
outpatient services provided by facilities in our Hospital segment by
multiplying actual patient admissions by the sum of gross inpatient revenues and
outpatient revenues, then dividing that result by gross inpatient revenues.
5. Income tax expense is calculated by multiplying 24% (the federal corporate
tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income
less NCI expense plus permanent differences, and non-deductible interest
expense.
6. Change versus prior year is presented on a same-facility system-wide basis
for USPI Ambulatory surgical cases and on a same-hospital basis for hospital
statistics.
7. Contract termination revenue recognized from the early conclusion of the RCM
Agreements is not included in net operating revenues.
Page 8
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services
company headquartered in Dallas. Our care delivery network includes United
Surgical Partners International, the largest ambulatory platform in the country,
which operates ambulatory surgery centers and surgical hospitals. We also
operate a national portfolio of acute care and specialty hospitals, other
outpatient facilities, a network of leading employed physicians and a global
business center in Manila, Philippines. Our Conifer Health Solutions subsidiary
provides revenue cycle management and value-based care services to hospitals,
health systems, physician practices, employers and other clients. Across the
Tenet enterprise, we are united by our mission to deliver quality, compassionate
care in the communities we serve. For more information, please visit
www.tenethealth.com.
Contact Information
Investor Contact Media Contact
Will McDowell Olivia E. Nadler
469-893-2387 469-893-6352
[email protected] [email protected]
Page 9
Non-GAAP Financial Measures
The Company believes the non-GAAP measures described below are useful to
investors and analysts because they present additional information on the
Company’s financial performance. Investors, analysts, Company management and the
Company’s Board of Directors utilize these non-GAAP measures, in addition to
GAAP measures, to track the Company’s financial and operating performance and
compare the Company’s performance to its peer companies, which use similar non-
GAAP financial measures in their presentations and earnings releases. The Human
Resources Committee of the Company’s Board of Directors also uses certain of
these measures to evaluate management’s performance for the purpose of
determining incentive compensation. Additional information regarding the purpose
and utility of specific non-GAAP measures used in this release is set forth
below.
• Adjusted EBITDA is defined by the Company as net income available (loss
attributable) to Tenet common shareholders before (1) the cumulative effect of
changes in accounting principles, (2) net loss attributable (income available)
to noncontrolling interests, (3) income (loss) from discontinued operations, net
of tax, (4) income tax benefit (expense), (5) gain (loss) from early
extinguishment of debt, (6) other non-operating income (expense), net, (7)
interest expense, (8) litigation and investigation benefit (costs), net of
insurance recoveries, (9) net gains (losses) on sales, consolidation and
deconsolidation of facilities, (10) impairment and restructuring charges and
acquisition-related costs, (11) depreciation and amortization, (12) income
(loss) from divested and closed businesses (i.e., health plan businesses) and
(13) revenue from contract termination. Revenue from contract termination
represents the present value of the $1.9 billion of consideration related to the
early termination of Conifer’s revenue cycle services agreement with
CommonSpirit (as further described in the Company’s Form 8-K dated February 2,
2026), net of amortization of an associated contract asset. Litigation and
investigation benefit (costs) excluded do not include ordinary course of
business malpractice and other litigation and related expenses.
• Adjusted diluted earnings (loss) per share is defined by the Company as
Adjusted net income available (loss attributable) to Tenet common shareholders,
divided by the weighted average diluted shares outstanding in the reporting
period.
• Adjusted net income available (loss attributable) to Tenet common shareholders
is defined by the Company as net income available (loss attributable) to Tenet
common shareholders before (1) income (loss) from discontinued operations, net
of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and
investigation benefit (costs), net of insurance recoveries, (4) net gains
(losses) on sales, consolidation and deconsolidation of facilities, (5)
impairment and restructuring charges and acquisition-related costs, (6) income
(loss) from divested and closed businesses (i.e., health plan businesses), (7)
revenue from contract termination and (8) the associated impact of these items
on taxes and noncontrolling interests. Revenue from contract termination
represents the present value of the $1.9 billion of consideration related to the
early termination of Conifer’s revenue cycle services agreement with
CommonSpirit (as further described in the Company’s Form 8-K dated February 2,
2026), net of amortization of an associated contract asset. Litigation and
investigation benefit (costs) excluded do not include ordinary course of
business malpractice and other litigation and related expenses.
• Free Cash Flow is defined by the Company as (1) net cash provided by (used in)
operating activities, less (2) purchases of property and equipment.
• Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash
provided by (used in) operating activities, less (2) purchases of property and
equipment.
• Adjusted net cash provided by (used in) operating activities is defined by the
Company as cash provided by (used in) operating activities prior to (1) payments
for restructuring charges, acquisition-related costs and litigation costs and
settlements, (2) net cash provided by (used in) operating activities from
discontinued operations and (3) cash received for contract termination defined
above.
The Company believes that Adjusted EBITDA is a useful measure, in part, because
certain investors and analysts use both historical and projected Adjusted
EBITDA, in addition to other GAAP and non-GAAP measures, as factors in
determining the estimated fair value of shares of the Company’s common stock.
Company management also regularly reviews the Adjusted EBITDA performance for
each operating segment. The Company does not use Adjusted EBITDA to measure
liquidity, but instead to measure operating performance.
The Company uses, and believes investors use, Free Cash Flow and Adjusted Free
Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from
the Company’s operations. The Company believes these measures are useful to
investors in evaluating its ability to fund distributions paid to noncontrolling
interests or for acquisitions, purchasing equity interests in joint ventures or
repaying debt.
These non-GAAP measures may not be comparable to similarly titled measures
reported by other companies. Because these measures exclude many items that are
included in the Company’s financial statements, they do not provide a complete
measure of the Company’s operating performance. For example, the Company’s
definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other
important uses of cash including (1) cash used to purchase businesses or joint
venture interests, or (2) any items that are classified as Cash Flows from
Financing Activities on the Company’s Consolidated Statement of Cash Flows,
including items such as (i) cash used to repay borrowings, or (ii) distributions
paid to noncontrolling interests. Accordingly, investors are encouraged to use
GAAP measures when evaluating the Company’s financial performance.
See corresponding reconciliations of the non-GAAP financial measures referred to
above to the most comparable GAAP financial measures in Tables #1 - 6 below.
Page 10
Tenet Healthcare Corporation
Financial Statements and Reconciliations
Third Quarter Earnings Release
Table of Contents
Description Page
Consolidated Statements of Operations 12
Consolidated Balance Sheets 14
Consolidated Statements of Cash Flows 15
Segment Reporting 16
Table #1–Reconciliations of 17
NetIncometoAdjusted Net Income
Table #2–Reconciliations of Net Income 18
toAdjusted EBITDA
Table #3–Reconciliations of Net Cash
Provided by Operating Activities to Free 19
Cash Flow and Adjusted Free Cash Flow
Table #4–Reconciliations of Outlook Net 20
Income to Outlook Adjusted Net Income
Table #5–Reconciliations of Outlook Net 21
Income to Outlook Adjusted EBITDA
Table #6–Reconciliations of Outlook Net
Cash Provided byOperating Activities to 22
Outlook Free Cash Flow and Outlook
Adjusted Free Cash Flow
Page 11
TENET HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
…
…
… T…
… M…
… E…
… S…
… 2… 3… % 2… % C…
──────────────────────────────────────────────────────────────────────────────
…
… $ 5… 1… % $ 5,… 10… % 6.5 %
…
…
… 6… 1… % — — % 10… %
…
…
…
…
… 64 1… % 64 1.2 % — %
…
…
…
…
…
…
… 2… 3… % 2,… 41… % -1… %
…
…
… 9… 1… % 931 17… % 5.6 %
…
… 1… 2… % 1,… 21… % 5.8 %
…
…
…
… 2… 3… % 218 4.1 %
…
…
…
…
… 37 0… % 23 0.4 %
…
…
…
…
…
… 6 0… % -11 -0… %
…
…
…
…
…
…
… -9 -… % -20 -0… %
…
…
…
…
… 1… 3… % 889 16… %
…
… -… -2…
…
…
… 37 29
…
…
…
…
… -5 —
…
…
…
…
… 1… 712
…
…
…
… -… -1…
…
… 1… 579
…
…
…
…
… 2… 237
…
…
…
…
…
…
…
… $ 1… $ 342
…
…
…
…
…
…
…
…
…
…
…
…
…
…
… $ 1… $ 3.…
… $ 1… $ 3.…
…
…
…
…
…
…
…
…
…
… 8… 8…
… 8… 8…
Page 12
TENET HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
…
…
… N…
… M…
… E…
… S…
… 2… 3… % 2… % C…
──────────────────────────────────────────────────────────────────────────────
…
… $ 1… 1… % $ 15… 10… % 5.3 %
…
…
… 1… 8… % — — % 10… %
…
…
…
…
… 1… 1… % 181 1.1 % -0… %
…
…
…
…
…
…
… 6… 3… % 6,… 41… % 1.5 %
…
…
… 2… 1… % 2,… 17… % 5.7 %
…
… 3… 2… % 3,… 21… % 4.6 %
…
…
…
… 6… 4… % 632 4.0 %
…
…
…
…
… 92 0… % 66 0.4 %
…
…
…
…
… 36 0… % 34 0.2 %
…
…
…
…
…
…
… -… -… % -4 — %
…
…
…
…
… 4… 2… % 2,… 16… %
…
… -… -6…
…
…
… 1… 80
…
…
…
…
… -5 —
…
…
…
…
… 4… 2,…
…
…
…
… -… -3…
…
… 3… 1,…
…
…
…
…
… 6… 687
…
…
…
…
…
…
…
… $ 2… $ 1,…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
… $ 3… $ 11…
… $ 3… $ 11…
…
…
…
…
…
…
…
…
…
… 8… 9…
… 8… 9…
Page 13
TENET HEALTHCARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Dollars in September 30, December 31,
millions) 2026 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets:
Cash and cash equivalents $ 2,674 $ 2,883
Accounts receivable 2,595 2,565
Inventories of supplies, 340 348
at cost
Assets held for sale 62 62
Other current assets 2,757 1,991
Total current assets 8,428 7,849
Investments and other 3,958 2,883
assets
Deferred income taxes 49 84
Property and equipment, at
cost, less
accumulated depreciation 6,290 6,315
and
amortization
Goodwill 11,641 11,198
Other intangible assets,
at cost, less 1,226 1,348
accumulated amortization
Total assets $ 31,592 $ 29,677
LIABILITIES AND EQUITY
Current liabilities:
Current portion of $ 164 $ 79
long-term debt
Accounts payable 1,387 1,360
Accrued compensation and 873 858
benefits
Professional and general
liability 317 276
reserves
Accrued interest payable 213 81
Income tax payable 22 —
Other current liabilities 2,342 1,809
Total current liabilities 5,318 4,463
Long-term debt, net of 13,079 13,092
current portion
Professional and general
liability 979 951
reserves
Defined benefit plan 238 245
obligations
Deferred income taxes 529 240
Other long-term 1,855 1,713
liabilities
Total liabilities 21,998 20,704
Commitments and
contingencies
Redeemable noncontrolling
interests in 2,179 2,956
equity of consolidated
subsidiaries
Equity:
Shareholders’ equity:
Common stock 8 8
Additional paid-in capital 5,236 4,914
Accumulated other -178 -181
comprehensive loss
Retained earnings 6,943 4,415
Common stock in treasury, -6,565 -4,936
at cost
Total shareholders’ equity 5,444 4,220
Noncontrolling interests 1,971 1,797
Total equity 7,415 6,017
Total liabilities and $ 31,592 $ 29,677
equity
Page 14
TENET HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Dollars in Nine Months Ended
millions) September 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 3,170 $ 1,723
Adjustments to
reconcile net income to
net cash provided by
operating
activities:
Depreciation and 661 632
amortization
Deferred income tax 324 51
expense
Stock-based 104 79
compensation expense
Impairment and
restructuring charges, 92 66
and acquisition-related
costs
Litigation and 36 34
investigation costs
Net gains on sales,
consolidation and -43 -4
deconsolidation of
facilities
Loss from early 5 —
extinguishment of debt
Equity in earnings of
unconsolidated
affiliates, net of -11 -13
distributions
received
Amortization of debt
discount and debt 16 18
issuance costs
Other items, net -11 -5
Changes in cash from
operating assets
and liabilities:
Accounts receivable -11 68
Inventories and other 211 -58
current assets
Income taxes 63 15
Accounts payable,
accrued expenses and -1,042 237
other current
liabilities
Other long-term 46 50
liabilities
Payments for
restructuring charges,
acquisition-related -103 -84
costs, and
litigation costs and
settlements
Net cash provided by
operating 3,507 2,809
activities
Cash flows from
investing activities:
Purchases of property -546 -646
and equipment
Purchases of businesses
or joint venture -201 -266
interests, net of cash
acquired
Proceeds from sales of
facilities and 11 18
other assets
Proceeds from sales of
marketable 66 74
securities and
long-term investments
Purchases of marketable
securities and -122 -69
long-term investments
Other items, net -26 3
Net cash used in -818 -886
investing activities
Cash flows from
financing activities:
Repayments of -2,087 -90
borrowings
Proceeds from 2,041 21
borrowings
Repurchases of common -1,615 -1,188
stock
Debt issuance costs -22 —
Distributions paid to
noncontrolling -614 -585
interests
Proceeds from the sale
of noncontrolling 33 27
interests
Purchases of
noncontrolling -583 -88
interests
Repayments of advances
from managed care — -33
payers
Taxes paid related to
net share
settlement, net of
proceeds from shares -84 -47
issued under
stock‑based
compensation
plans
Other items, net 33 16
Net cash used in -2,898 -1,967
financing activities
Net decrease in cash
and cash -209 -44
equivalents
Cash and cash
equivalents at 2,883 3,019
beginning
of period
Cash and cash
equivalents at end of $ 2,674 $ 2,975
period
Supplemental
disclosures:
Interest paid, net of
capitalized $ -464 $ -499
interest
Income tax payments, $ -493 $ -329
net
Page 15
TENET HEALTHCARE CORPORATION
SEGMENT REPORTING
(Unaudited)
(Do… Three Nine
in Mont… Mon…
mil… Ended End…
Net Sept… Sep…
ope… 30, 30,
rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Amb… $ 1,371 $ 1,275 $ 4,079 $ 3,7…
Care
Hos…
Ope… 4,260 4,014 12,5… 12,…
and
Ser…
Tot… $ 5,631 $ 5,289 $ 16,6… $ 15,…
Equ…
in
ear…
of
unc…
aff…
Amb… $ 64 $ 63 $ 179 $ 176
Care
Hos…
Ope… — 1 1 5
and
Ser…
Tot… $ 64 $ 64 $ 180 $ 181
Adj…
EBI…
Amb… $ 537 $ 492 $ 1,563 $ 1,4…
Care
Hos…
Ope… 818 607 2,258 1,9…
and
Ser…
Tot… $ 1,355 $ 1,099 $ 3,821 $ 3,3…
Adj…
EBI…
mar…
Amb… 39.2 % 38.6 % 38.3 % 38.7 %
Care
Hos…
Ope… 19.2 % 15.1 % 18.0 % 16.1 %
and
Ser…
Tot… 24.1 % 20.8 % 23.0 % 21.4 %
Cap…
exp…
Amb… $ 40 $ 38 $ 110 $ 90
Care
Hos…
Ope… 158 242 436 556
and
Ser…
Tot… $ 198 $ 280 $ 546 $ 646
Page 16
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #1 – Reconciliations of Net Income Available to Tenet Healthcare
Corporation Common Shareholders to Adjusted Net Income Available to Common
Shareholders
(Unaudited)
(Doll…
in
milli…
except Three Nine
per Months Months
share Ended Septe… Ended Septe…
amoun… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
income
avail…
to
Tenet $ 1,000 $ 342 $ 2,528 $ 1,036
Healt…
Corpo…
common
share…
Less:
Reven…
from 646 — 1,472 —
contr…
termi…
Impai…
and
restr…
charg… -37 -23 -92 -66
and
acqui…
costs
Litig…
and
inves… -6 11 -36 -34
benef…
(cost…
Net
gains
on
sales,
conso… 9 20 43 4
and
decon…
of
facil…
Loss
from
early -5 — -5 —
extin…
of
debt
Tax
and
nonco…
inter… -142 6 -325 21
impact
of
above
items
Adjus…
net
income
avail… $ 535 $ 328 $ 1,471 $ 1,111
to
common
share…
Dilut…
earni… $ 12.41 $ 3.86 $ 30.08 $ 11.28
per
share
Less:
Reven…
from 8.01 — 17.51 —
contr…
termi…
Impai…
and
restr…
charg… -0.46 -0.26 -1.09 -0.72
and
acqui…
costs
Litig…
and
inves… -0.07 0.12 -0.43 -0.37
benef…
(cost…
Net
gains
on
sales,
conso… 0.11 0.23 0.51 0.04
and
decon…
of
facil…
Loss
from
early -0.06 — -0.06 —
extin…
of
debt
Tax
and
nonco…
inter… -1.76 0.07 -3.86 0.23
impact
of
above
items
Adjus…
dilut…
earni… $ 6.64 $ 3.70 $ 17.50 $ 12.10
per
share
Weigh…
avera…
basic
shares 80,134 87,951 83,486 91,109
outst…
(in
thous…
Weigh…
avera…
dilut…
shares 80,600 88,610 84,053 91,805
outst…
(in
thous…
Page 17
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #2 – Reconciliations of Net Income Available to Tenet Healthcare
Corporation Common Shareholders to Adjusted EBITDA
(Unaudited)
Three Nine
(Do… Mont… Mon…
in Ended Sept… End… Sept…
mil… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
inc…
ava…
to
Ten… $ 1,000 $ 342 $ 2,528 $ 1,0…
Hea…
Cor…
com…
sha…
Les…
Net
inc…
ava… -219 -237 -642 -687
to
non…
int…
Net 1,219 579 3,170 1,7…
inc…
Inc…
tax -360 -133 -881 -396
exp…
Loss
from
ear… -5 — -5 —
ext…
of
debt
Oth…
non… 37 29 121 80
inc…
net
Int… -203 -206 -612 -616
exp…
Ope… 1,750 889 4,547 2,6…
inc…
Rev…
from 646 — 1,472 —
con…
ter…
Dep…
and -217 -218 -661 -632
amo…
Imp…
and
res…
cha… -37 -23 -92 -66
and
acq…
cos…
Lit…
and
inv… -6 11 -36 -34
ben…
(co…
Net
gai…
on
sal…
con… 9 20 43 4
and
dec…
of
fac…
Adj… $ 1,355 $ 1,099 $ 3,821 $ 3,3…
EBI…
Net
ope… $ 5,631 $ 5,289 $ 16,6… $ 15,…
rev…
Net
inc…
ava…
to
Ten…
Hea…
Cor…
com… 17.8 % 6.5 % 15.2 % 6.6 %
sha…
as a
%
of
net
ope…
rev…
Adj…
EBI…
as a
% of
net 24.1 % 20.8 % 23.0 % 21.4 %
ope…
rev…
(Ad…
EBI…
mar…
Page 18
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #3 – Reconciliations of Net Cash Provided by Operating Activities to
Free Cash Flow and Adjusted Free Cash Flow
(Unaudited)
(Dollars in millions) 2026 Q3 YTD
─────────────────────────────────────────────────────────────────────────────
Net cash provided by operating $ 1,281 $ 3,507
activities
Purchases of property and equipment -198 -546
Free cash flow $ 1,083 $ 2,961
Net cash used in investing activities $ -298 $ -818
Net cash used in financing activities $ -479 $ -2,898
Net cash provided by operating $ 1,281 $ 3,507
activities
Less:
Payments for restructuring charges,
acquisition-related costs, and -19 -103
litigation costs and settlements
Cash received for contract termination — 540
Adjusted net cash provided by operating 1,300 3,070
activities
Purchases of property and equipment -198 -546
Adjusted free cash flow $ 1,102 $ 2,524
2025
(Dollars in millions) Q3 YTD
───────────────────────────────────────────────────────────────────────
Net cash provided by operating $ 1,058 $ 2,809
activities
Purchases of property and equipment -280 -646
Free cash flow $ 778 $ 2,163
Net cash used in investing activities $ -385 $ -886
Net cash used in financing activities $ -323 $ -1,967
Net cash provided by operating $ 1,058 $ 2,809
activities
Less:
Payments for restructuring charges,
acquisition-related costs, and -3 -84
litigation costs and settlements
Adjusted net cash provided by operating 1,061 2,893
activities
Purchases of property and equipment -280 -646
Adjusted free cash flow $ 781 $ 2,247
Page 19
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare
Corporation Common Shareholders to Outlook Adjusted Net Income Available to
Common Shareholders
(Unaudited)
(Dollars in millions, except per
share
amounts) FY 2026 Low High
──────────────────────────────────────────────────────────────────────────────
Net income available to Tenet
Healthcare $ 2,973 $ 3,078
Corporation common shareholders
Less:
Revenue from contract termination 1,650 1,650
Impairment and restructuring
charges,
acquisition-related costs, and -180 -150
litigation costs and
settlements(1)
Net gains on sales, consolidation
and 43 43
deconsolidation of facilities(2)
Loss from early extinguishment of -5 -5
debt(2)
Tax and noncontrolling interests
impact -365 -370
of above items
Adjusted net income available to
common $ 1,830 $ 1,910
shareholders
Diluted earnings per share $ 35.82 $ 37.08
Less:
Revenue from contract termination 19.88 19.88
Impairment and restructuring
charges, -2.17 -1.81
acquisition-related costs, and
litigation costs and settlements
Net gains on sales, consolidation
and 0.52 0.52
deconsolidation of facilities
Loss from early extinguishment of -0.06 -0.06
debt
Tax and noncontrolling interests
impact -4.40 -4.46
of above items
Adjusted diluted earnings per $ 22.05 $ 23.01
share
Weighted average dilutive shares 83,000 83,000
outstanding (in thousands)
(1) The figures shown represent
the
Company's estimate for
restructuring
charges plus the actual
year-to-date
results for impairment and
restructuring
charges, acquisition-related
costs, and
litigation costs and settlements.
The
Company does not generally
forecast
impairment charges,
acquisition-related
costs, and litigation costs and
settlements because it does not
believe
that it can forecast these items
with
sufficient accuracy since some of
these
items are indeterminable at the
time the
Company provides its financial
Outlook.
(2) The Company does not generally
forecast net gains (losses) on
sales,
consolidation and deconsolidation
of
facilities or gains (losses) from
early
extinguishment of debt because the
Company does not believe that it
can
forecast these items with
sufficient
accuracy since it is
indeterminable at
the time the Company provides its
financial Outlook. The figures
shown
relate to transactions that have
already
occurred in 2026.
Page 20
T
ENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare
Corporation Common Shareholders to Outlook Adjusted EBITDA
(Unaudited)
(Dollars in millions) FY 2026 Low High
──────────────────────────────────────────────────────────────────────────────
Net income available to
Tenet Healthcare $ 2,973 $ 3,078
Corporation common
shareholders
Less:
Net income available to
noncontrolling -910 -960
interests
Income tax expense -1,135 -1,170
Interest expense -825 -815
Loss from early
extinguishment of -5 -5
debt(2)
Other non-operating income, 150 200
net
Net gains on sales,
consolidation and 43 43
deconsolidation of
facilities(2)
Impairment and restructuring
charges,
acquisition-related costs, -180 -150
and
litigation costs and
settlements(1)
Depreciation and -865 -915
amortization
Revenue from contract 1,650 1,650
termination
Adjusted EBITDA $ 5,050 $ 5,200
Net income available to
Tenet Healthcare $ 2,973 $ 3,078
Corporation common
shareholders
Net operating revenues $ 22,050 $ 22,450
Net income available to
Tenet Healthcare
Corporation common 13.5 % 13.7 %
shareholders as a %
of net operating revenues
Adjusted EBITDA as a % of
net operating 22.9 % 23.2 %
revenues (Adjusted EBITDA
margin)
(1) The figures shown
represent the
Company's estimate for
restructuring
charges plus the actual
year-to-date
results for impairment and
restructuring
charges, acquisition-related
costs, and
litigation costs and
settlements. The
Company does not generally
forecast
impairment charges,
acquisition-related
costs, and litigation costs
and
settlements because it does
not believe
that it can forecast these
items with
sufficient accuracy since
some of these
items are indeterminable at
the time the
Company provides its
financial Outlook.
(2) The Company does not
generally
forecast net gains (losses)
on sales,
consolidation and
deconsolidation of
facilities or gains (losses)
from early
extinguishment of debt
because the
Company does not believe
that it can
forecast these items with
sufficient
accuracy since it is
indeterminable at
the time the Company
provides its
financial Outlook. The
figures shown
relate to transactions that
have already
occurred in 2026.
Page 21
TENET HEALTHCARE CORPORATION
Additional Supplemental Non-GAAP disclosures
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities
to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow
(Unaudited)
FY 2026
(Dollars in millions) Low High
───────────────────────────────────────────────────────────────────────────
Net cash provided by operating $ 3,885 $ 4,315
activities
Purchases of property and equipment -700 -800
Free cash flow $ 3,185 $ 3,515
Net cash provided by operating $ 3,885 $ 4,315
activities
Less:
Payments for restructuring charges,
acquisition-related costs and litigation -180 -150
costs and settlements(1)
Cash received for contract termination 540 540
Adjusted net cash provided by operating 3,525 3,925
activities
Purchases of property and equipment -700 -800
Adjusted free cash flow(2) $ 2,825 $ 3,125
(1) The figures shown represent the
Company's estimate for restructuring
payments plus the actual year-to-date
payments for restructuring charges,
acquisition-related costs, and
litigation costs or settlements. The
Company does not generally forecast
payments for acquisition-related costs,
and litigation costs and settlements
because it does not believe that it can
forecast these items with sufficient
accuracy since some of these items are
indeterminable at the time the Company
provides its financial Outlook.
(2) The Company’s definition of Adjusted
Free Cash Flow does not include other
important uses of cash including (1)
cash used to purchase businesses or
joint venture interests, or (2) any
items that are classified as Cash Flows
From Financing Activities on the
Company’s Consolidated Statement of Cash
Flows, including items such as (i) cash
used to repay borrowings, and (ii)
distributions paid to noncontrolling
interests.
Page 22